These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

818 related articles for article (PubMed ID: 31741437)

  • 21. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications.
    Vallon V
    Am J Hypertens; 2024 Oct; 37(11):841-852. PubMed ID: 39017631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renoprotective Effects of SGLT2 Inhibitors.
    Vallon V
    Heart Fail Clin; 2022 Oct; 18(4):539-549. PubMed ID: 36216484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of SGLT2 inhibitor and dietary NaCl on glomerular hemodynamics assessed by micropuncture in diabetic rats.
    Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2021 May; 320(5):F761-F771. PubMed ID: 33645318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
    Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
    Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
    Thomas MC; Cherney DZI
    Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
    Packer M
    Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney.
    Gronda E; Vanoli E; Iacoviello M; Caldarola P; Gabrielli D; Tavazzi L
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
    Kale A; Sharma A; Anders HJ; Gaikwad AB
    Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
    Kim NH; Kim NH
    Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors.
    Sen T; Heerspink HJL
    Cell Metab; 2021 Apr; 33(4):732-739. PubMed ID: 33691091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
    Zhang Y; Thai K; Kepecs DM; Gilbert RE
    PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.
    Koh ES; Kim GH; Chung S
    Endocrinol Metab (Seoul); 2023 Aug; 38(4):359-372. PubMed ID: 37482684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A role for tubular Na
    Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
    Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.